Literature DB >> 16730624

Azathioprine and inhibition of the anticoagulant effect of warfarin: evidence from a case report and a literature review.

Heng Joo Ng1, Mark A Crowther.   

Abstract

BACKGROUND: Warfarin and azathioprine may be prescribed concurrently in patients requiring both anticoagulation and immunosuppression. However, a potential interaction between the 2 drugs, resulting in an increased warfarin requirement, may be overlooked in clinical practice. CASE
SUMMARY: A 67-year-old woman was treated with warfarin (initial mean dose, 24 mg/wk [3.5 mg/d]) for >3 years for recurrent deep vein thrombosis associated with systemic lupus erythematosus. Soon after commencing warfarin, azathioprine 150 mg/d was introduced for its steroid-sparing effect. Warfarin was titrated to a mean dose of 60 to 75 mg/wk (8.5-10.5 mg/d) over the next 18 months. Her dose of azathioprine was then increased to 200 mg/d. Subtherapeutic international normalized ratio (INR) levels required an increase in the warfarin dose to a mean of 130 mg/wk (18.5 mg/d). Subsequent discontinuation of azathioprine resulted in a dramatic increase in her INR levels (from 1.8 to 14.0 four weeks after discontinuation). DISCUSSION: A temporal relationship, demonstrating the interaction between warfarin and azathioprine, was evident at various times during therapy for our patient. This case, together with 7 additional published cases, is comprehensively reviewed here using previously described criteria for establishing a definite interaction between warfarin and other drugs.
CONCLUSIONS: The evidence supports a clinically important inhibitory action of azathioprine on warfarin and calls for closer monitoring of INR levels when azathioprine doses are altered during concurrent administration with warfarin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730624     DOI: 10.1016/j.amjopharm.2006.03.001

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  6 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.

Authors:  Nathalie Costedoat-Chalumeau; Zahir Amoura; Jean-Sébastien Hulot; Guy Aymard; Gaëlle Leroux; Donata Marra; Philippe Lechat; Jean-Charles Piette
Journal:  Ann Rheum Dis       Date:  2007-02-26       Impact factor: 19.103

3.  Azathioprine-induced warfarin resistance.

Authors:  Sara R Vazquez; Matthew T Rondina; Robert C Pendleton
Journal:  Ann Pharmacother       Date:  2008-05-27       Impact factor: 3.154

Review 4.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Authors:  Alexander Teml; Elke Schaeffeler; Klaus R Herrlinger; Ulrich Klotz; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 5.577

5.  Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more.

Authors:  Maia Gavronski; Sirpa Hartikainen; Alexander Zharkovsky
Journal:  Pharm Pract (Granada)       Date:  2012-03-31

6.  A case of cerebral venous sinus thrombosis associated with Crohn's disease: dilemma in management.

Authors:  Younghoon Kwon; Ryan J Koene; Yeilim Cho
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-11-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.